Evidence map›Paper›PMID 28267152›Full record

Trial reportTranslational psychiatry2017

Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.

G Savulich, R Riccelli, L Passamonti, M Correia, J F W Deakin, R Elliott, R S A Flechais, A R Lingford-Hughes, J McGonigle, A Murphy and 11 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. The Effects of Adverse Life Events on Brain Development in the ABCD StudymedRxiv : the preprint server for health sciences · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

G SavulichDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
R RiccelliBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
L PassamontiDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
M CorreiaCognition and Brain Sciences Unit, Medical Research Council, Cambridge, UK.
J F W DeakinInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.
R ElliottInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.
R S A FlechaisCentre for Neuropsychopharmacology, Imperial College London, London, UK.
A R Lingford-HughesCentre for Neuropsychopharmacology, Imperial College London, London, UK.
J McGonigleCentre for Neuropsychopharmacology, Imperial College London, London, UK.
A MurphyInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.
D J NuttCentre for Neuropsychopharmacology, Imperial College London, London, UK.
C OrbanCentre for Neuropsychopharmacology, Imperial College London, London, UK.
L M PatersonCentre for Neuropsychopharmacology, Imperial College London, London, UK.
L J ReedCentre for Neuropsychopharmacology, Imperial College London, London, UK.
D G SmithDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
J SucklingDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
R TaitDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
E M TaylorInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.
B J SahakianDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
T W RobbinsBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
K D ErscheDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
University of Cambridge · GBImperial College London · GBUniversity of Manchester · GBMedical Research Council · GB

Funding

Medical Research Council MC_U105579212Medical Research Council MC_UU_00005/14Wellcome Trust
6 · The paper itself

Abstract

Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence. Although the endogenous opioid system has been implicated in emotion regulation, the effects of mu-opioid receptor blockade on brain systems underlying negative emotional processing are not clear in addiction. Individuals meeting criteria for alcohol dependence alone (n=18, alcohol) and in combination with cocaine and/or opioid dependence (n=21, alcohol/drugs) and healthy individuals without a history of alcohol or drug dependence (n=21) were recruited. Participants were alcohol and drug abstinent before entered into this double-blind, placebo-controlled, randomized, crossover study. Functional magnetic resonance imaging was used to investigate brain response while viewing aversive and neutral images relative to baseline on 50 mg of naltrexone and placebo. We found that naltrexone modulated task-related activation in the medial prefrontal cortex and functional connectivity between the anterior cingulate cortex and the hippocampus as a function of childhood adversity (for aversive versus neutral images) in all groups. Furthermore, there was a group-by-treatment-by-condition interaction in the right amygdala, which was mainly driven by a normalization of response for aversive relative to neutral images under naltrexone in the alcohol/drugs group. We conclude that early childhood adversity is one environmental factor that influences pharmacological response to naltrexone. Pharmacotherapy with naltrexone may also have some ameliorative effects on negative emotional processing in combined alcohol and drug dependence, possibly due to alterations in endogenous opioid transmission or the kappa-opioid receptor antagonist actions of naltrexone.

Indexed as

Adult Survivors of Child Adverse EventsAdultAlcoholismAmygdalaBrainCase-Control StudiesCocaine-Related DisordersCross-Over StudiesCuesDouble-Blind MethodFemaleFunctional NeuroimagingGyrus CinguliHippocampusHumansMagnetic Resonance ImagingNaltrexoneNarcotic Antagonists

Identifiers

PMID28267152
PMCPMC5416677
OpenAlexW2593056641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.